| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Medpace Holdings, Inc. Common Stock$461.6
-5.9 (-1.26%)
Market Cap
14.09 B
EPS
15.65
P/E Ratio
32.27 $
Value Trade
106.73 M
SEC Financials
Q4 2025Dilution Risk
Revenue
708.45 M
Operating CF
178.31 M
Total Assets
1.98 B
Total Liabilities
1.52 B
Equity
459.07 M
D/E Ratio
12,345
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
497.05 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
Feb 10, 2026
Overview
Volume
224.69 K
52 Week Range
250.05 - 628.92
% held by Insiders
19.45 %
% held by Institutions
86.58 %
Enterprise Value
13.73 B
Total Shares
28.37 M
Short %
9.13 %
Float Shares
22.50 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in MEDP
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
MEDP
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
MEDP
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
MEDP
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
MEDP Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
MEDP Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-06-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-06-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-06-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-MEDP
Jun 16, 2026Medpace Holdings, Inc. to Report Second Quarter 2026 Financial Results on July 22, 2026
Medpace Holdings, Inc. has announced that it will report its financial results for the second quarter of 2026 on July 22, 2026. This announcement provides stakeholders with a timeline for when to expect the financial performance details of the company. The report will likely include insights into the company's operations and financial health.
Read more →-MEDP
Apr 22, 2026Medpace Holdings, Inc. Reports First Quarter 2026 Results
Medpace Holdings, Inc. has reported its financial results for the first quarter of 2026. The article does not provide specific details about the performance metrics or any significant events related to the results. The information appears to be limited and lacks context.
Read more →-MEDP
Mar 25, 2026Medpace Holdings, Inc. to Report First Quarter 2026 Financial Results on April 22, 2026
Medpace Holdings, Inc. announced it will report its first quarter 2026 financial results on April 22, 2026. A conference call will follow on April 23, 2026, at 9:00 a.m. ET for discussion of these results. Interested participants must register in advance, and a webcast will also be available.
Read more →-MEDP
Feb 10, 2026Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2025 Results
Medpace Holdings, Inc. reported strong financial results for Q4 and full year 2025, with revenues increasing by 32% year-over-year in Q4 and 20% for the full year. The company also announced a positive outlook for 2026, projecting revenue growth between 8.9% and 12.8%. However, total direct costs and SG&A expenses have risen, impacting net income margins.
Read more →Competitive Position
How MEDP ranks across every disease it competes inCompetitive Position is a premium feature
See how MEDP ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial